TREXAVIVE is a subcutaneous therapy designed to treat major depressive disorder and treatment resistant depression. It works by targeting both GABA and opioid pathways – offering a dualmechanism approach that is fast-acting, non dissociative, and non-sedating.
Now funded by the Department of Veterans’ Affairs (DVA) for
eligible patients.
MDD, TRD
GABAergic + opioid modulation
Subcutaneous injection
No sedation – No dissociation – No addiction liability
What is TREXAVIVE? A new treatment designed to help when others haven’t. It targets key brain systems involved in depression, without the side effects often seen in traditional medications.
What to do next? Ask your doctor or psychiatrist about TREXAVIVE – You may be eligible if you’re living with major depression, or treatment resistant depression.
DVA-Funded Access TREXAVIVE is available to eligible
veterans through the Department of Veterans’ Affairs.
How to access it – Speak to your GP or mental health
provider – Provide your DVA details for assessment.
TREXAVIVE is Trexapharm’s lead therapy – a purpose-built, repurposed intervention for high-need mental health conditions. Already approved for use with DVA funding, its trajectory reflects our broader platform opportunity.